Ortho Dermatologics announces two-year findings from pivotal phase 3 study of SILIQ™
Ortho Dermatologics announced results from the Pivotal Phase 3 long-term extension study (AMAGINE-2), which demonstrated that SILIQ™ (brodalumab) injection provided sustained high levels of skin clearance over more than two years in patients with moderate-to-severe psoriasis. October 12, 2017